Scancell : COVIDITY programme to start Phase I in H221

Scancell

COVIDITY programme to start Phase I in H221

22 June 2021

• Scancell has announced details of its planned Phase I clinical study for its COVIDITY second generation COVID-19 vaccine programme. Two lead bivalent vaccine candidates, known as SCOV1 and SCOV2, will be studied in trials in both South Africa and the UK. Subject to local swift regulatory approvals the studies are expected to start in H221.
• Following the company's application to SAHPRA (South African Health Products Regulatory Authority), the first part of the trial will be performed at the University of Cape Town Lung Institute on COVID-19-naïve unvaccinated, healthy adult volunteers (this cannot be done in the UK due to the success of the vaccination programme there). The two vaccine candidates will be studied in two different dose levels employing two separate needle- free injection formulations. The primary objective is assessing the safety and immunogenicity of SCOV1 and SCOV2, with levels of virus-neutralising antibodies (VNAbs) of key importance.
• The second part is subject to Medicines and Healthcare products Regulatory Agency (MHRA) approval based on results from Part 1. This will evaluate SCOV2 in healthy volunteers who have received two doses of any currently approved vaccine. The objective is to assess the level of immune response against current and potential future SARS-Cov-2 variants of concern (VoC).
• COVIDITY is a second-generation vaccine programme based on a modification of Scancell's ImmunoBody DNA vaccine technology. Unlike currently approved vaccines it targets both the N and S viral antigens. Recently publishedpreclinical data shows strong pro-inflammatoryT-cell responses to both the N and S proteins, with these responses being significantly enhanced by fusing the nucleocapsid sequence to a modified Fc utilising the company's AvidiMab technology.
• COVIDITY is a collaboration between Scancell, the Centre for Research on Global Virus Infections and the Biodiscovery Institute at the University of Nottingham, and Nottingham Trent University. The programme receives funding from Innovate UK.

Trinity Delta view: Scancell is well funded to deliver on the undoubted potential

of its three novel inter-related technology platforms: ImmunoBody, Moditope, and AvidiMab. Although the COVIDITY programme provides a high visibility showcase, we see a greater, longer-term, value in their applicability as treatments for many types of solid tumours. For example, ImmunoBody vaccines target dendritic cells and, importantly, stimulate both CD4 and CD8 T cells. These cancer vaccines can used as monotherapy or in combinations, with, say, checkpoint inhibitors.

Price	21.25p
Market Cap	£175m
Primary exchange	AIM
Sector	Healthcare
Company Codes	SCLP.L
Corporate client	Yes

Company description:

Scancell is a clinical-stage immuno- oncology specialist that has three technology platforms. Two flexible therapeutic vaccine platforms are progressing through development. ImmunoBody and Moditope induce high avidity cytotoxic CD8 and CD4 responses, respectively, with the potential to treat various cancers.

Analysts

Lala Gregorek

[e-mail][phone]

Franc Gregori

[e-mail][phone]

Trinity Delta

Scancell

Lala Gregorek	[e-mail]
	[phone]
Franc Gregori	[e-mail]
	[phone]

Disclaimer

Trinity Delta Research Limited ("TDRL"; firm reference number: 725161), which trades as Trinity Delta, is an appointed representative of Equity Development Limited ("ED"). The contents of this report, which has been prepared by and is the sole responsibility of TDRL, have been reviewed, but not independently verified, by ED which is authorised and regulated by the FCA, and whose reference number is 185325.

ED is acting for TDRL and not for any other person and will not be responsible for providing the protections provided to clients of TDRL nor for advising any other person in connection with the contents of this report and, except to the extent required by applicable law, including the rules of the FCA, owes no duty of care to any other such person. No reliance may be placed on ED for advice or recommendations with respect to the contents of this report and, to the extent it may do so under applicable law, ED makes no representation or warranty to the persons reading this report with regards to the information contained in it.

In the preparation of this report TDRL has used publicly available sources and taken reasonable efforts to ensure that the facts stated herein are clear, fair and not misleading, but make no guarantee or warranty as to the accuracy or completeness of the information or opinions contained herein, nor to provide updates should fresh information become available or opinions change.

Any person who is not a relevant person under section of Section 21(2) of the Financial Services & Markets Act 2000 of the United Kingdom should not act or rely on this document or any of its contents. Research on its client companies produced by TDRL is normally commissioned and paid for by those companies themselves ('issuer financed research') and as such is not deemed to be independent, as defined by the FCA, but is 'objective' in that the authors are stating their own opinions. The report should be considered a marketing communication for purposes of the FCA rules. It has not been prepared in accordance with legal requirements designed to promote the independence of investment research and it is not subject to any prohibition on dealing ahead of the dissemination of investment research. TDRL does not hold any positions in any of the companies mentioned in the report, although directors, employees or consultants of TDRL may hold positions in the companies mentioned. TDRL does impose restrictions on personal dealings. TDRL might also provide services to companies mentioned or solicit business from them.

This report is being provided to relevant persons to provide background information about the subject matter of the note. This document does not constitute, nor form part of, and should not be construed as, any offer for sale or purchase of (or solicitation of, or invitation to make any offer to buy or sell) any Securities (which may rise and fall in value). Nor shall it, or any part of it, form the basis of, or be relied on in connection with, any contract or commitment whatsoever. The information that we provide is not intended to be, and should not in any manner whatsoever be, construed as personalised advice. Self-certification by investors can be completed free of charge at www.fisma.org. TDRL, its affiliates, officers, directors and employees, and ED will not be liable for any loss or damage arising from any use of this document, to the maximum extent that the law permits.

Copyright 2021 Trinity Delta Research Limited. All rights reserved.

More information is available on our website: www.trinitydelta.org

Trinity Delta, 80 Cheapside, London, EC2V 6EE. Contact: [e-mail]